Eldred Rock Partners LLC Buys 1,854 Shares of Thermo Fisher Scientific Inc. $TMO

Eldred Rock Partners LLC increased its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.5% during the second quarter, Holdings Channel reports. The institutional investor owned 30,420 shares of the medical research company’s stock after purchasing an additional 1,854 shares during the period. Thermo Fisher Scientific comprises about 3.3% of Eldred Rock Partners LLC’s portfolio, making the stock its 14th largest holding. Eldred Rock Partners LLC’s holdings in Thermo Fisher Scientific were worth $15,251,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Chesley Taft & Associates LLC increased its holdings in shares of Thermo Fisher Scientific by 1.1% during the second quarter. Chesley Taft & Associates LLC now owns 42,333 shares of the medical research company’s stock valued at $21,224,000 after acquiring an additional 470 shares in the last quarter. Professional Advisory Services Inc. grew its position in Thermo Fisher Scientific by 9.8% in the 2nd quarter. Professional Advisory Services Inc. now owns 64,819 shares of the medical research company’s stock valued at $32,498,000 after purchasing an additional 5,804 shares during the period. Community Trust & Investment Co. increased its stake in Thermo Fisher Scientific by 2.1% during the 2nd quarter. Community Trust & Investment Co. now owns 39,072 shares of the medical research company’s stock valued at $19,589,000 after purchasing an additional 819 shares in the last quarter. FNY Investment Advisers LLC bought a new position in shares of Thermo Fisher Scientific in the second quarter valued at $75,000. Finally, Castle Rock Wealth Management LLC grew its holdings in shares of Thermo Fisher Scientific by 9.5% during the second quarter. Castle Rock Wealth Management LLC now owns 4,054 shares of the medical research company’s stock valued at $2,081,000 after buying an additional 353 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Analyst Ratings Changes

TMO has been the topic of a number of analyst reports. Jefferies Financial Group restated a “buy” rating and issued a $630.00 target price on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Robert W. Baird decreased their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. KeyCorp reissued an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. Wells Fargo & Company cut their target price on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. Finally, Evercore set a $570.00 price target on Thermo Fisher Scientific in a report on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $619.41.

Insider Buying and Selling

In other Thermo Fisher Scientific news, VP Lisa P. Britt sold 5,850 shares of the company’s stock in a transaction dated Thursday, August 6th. The stock was sold at an average price of $580.00, for a total value of $3,393,000.00. Following the transaction, the vice president directly owned 14,784 shares in the company, valued at $8,574,720. This represents a 28.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc N. Casper sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $574.45, for a total transaction of $2,872,250.00. Following the completion of the transaction, the chief executive officer owned 9,608 shares in the company, valued at approximately $5,519,315.60. This trade represents a 34.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 21,250 shares of company stock worth $12,235,950. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $593.11 on Friday. The business’s 50 day simple moving average is $517.63 and its 200 day simple moving average is $510.61. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a market cap of $219.30 billion, a price-to-earnings ratio of 31.90, a PEG ratio of 2.36 and a beta of 0.85. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. The business had revenue of $11.99 billion for the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company’s revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $4.28 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio is presently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.